◎ Sugi Atlas

Atlas / Drug / Prednisone

Prednisone

drug
On this page

Also known as 3en3hg4wswCortanCortancylDecortinDecortisylDehydrocortisoneDelta-domeDeltasoneFernisoneLiquid predLodotraMetacortandracinMeticortenNSC-10023OrasoneParacortPrednicen-mPrednisonaPrednisone anhydrous

Summary

Prednisone (CHEMBL635) is an approved small-molecule prodrug (ATC A07EA03) targeting NR3C1; indicated across 225 conditions including rheumatoid arthritis and pneumonia.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: A07EA03 (+1 more)
  • Targets: 1 (NR3C1)
  • Indications: 225 conditions
  • Clinical trials: 1,357
  • Chemistry: 358.4 Da · C21H26O5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL635
NamePrednisone
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5865
ChEBICHEBI:8382
ATCA07EA03, H02AB07
Molecular formulaC21H26O5
Molecular weight358.4
InChIKeyXOFYZVNMUHMLCC-ZPOLXVRWSA-N

SMILES: C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C

IUPAC name: (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione

ChEBI definition: A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a β-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Pharmacological roles (ChEBI): prodrug, anti-inflammatory drug, antineoplastic agent, immunosuppressive agent, adrenergic agent.

Also known as: 3en3hg4wsw, Cortan, Cortancyl, Decortin, Decortisyl, Dehydrocortisone, Delta-dome, Deltasone, Fernisone, Liquid pred, Lodotra, Metacortandracin

Patent coverage: 50,972 distinct patent families (190,796 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
NR3C1Glucocorticoid receptorFull agonist6.280.9%P04150

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Nuclear receptor ROR-gamma, Equilibrative nucleoside transporter 1, Glucocorticoid receptor, Progesterone receptor, Menin/Histone-lysine N-methyltransferase MLL, Aldehyde dehydrogenase 1A1, 3-hydroxyacyl-CoA dehydrogenase type-2, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
NR3C17.54Kd29nMCHEMBL_ACT_22449309
NR3C16.57AC50268nMCHEMBL_ACT_25175426
NR3C16.28Ki521nMCHEMBL_ACT_7734869
NR3C15.94IC501146nMCHEMBL_ACT_7734868
P514505.45Potency3548nMCHEMBL_ACT_4770100
ALDH1A15Potency10000nMCHEMBL_ACT_4119660

Target pathways

Aggregated over 1 target gene(s): NR3C1.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand1NR3C1
Nuclear Receptor transcription pathway1NR3C1
SUMOylation of intracellular receptors1NR3C1
PTK6 Expression1NR3C1
Regulation of RUNX2 expression and activity1NR3C1
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes1NR3C1
Potential therapeutics for SARS1NR3C1
Regulation of NPAS4 gene transcription1NR3C1

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II1
regulation of gluconeogenesis1
chromatin organization1
regulation of DNA-templated transcription1
regulation of transcription by RNA polymerase II1
apoptotic process1
chromosome segregation1
signal transduction1
glucocorticoid metabolic process1
response to wounding1
gene expression1
microglia differentiation1
adrenal gland development1
nuclear receptor-mediated steroid hormone signaling pathway1
regulation of glucocorticoid biosynthetic process1

Indications & clinical

Indications

225 indications (72 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
rheumatoid arthritis4MONDO:0008383EFO:0000685
pneumonia4MONDO:0005249EFO:0003106
allergic rhinitis4MONDO:0011786EFO:0005854
Crohn disease4MONDO:0005011EFO:0000384
ulcerative colitis4MONDO:0005101EFO:0000729
polymyositis4MONDO:0019127EFO:0003063
seasonal allergic rhinitis4MONDO:0005324EFO:0003956
gout4MONDO:0005393EFO:0004274
non-autoimmune hemolytic anemia4MONDO:0021559EFO:0005558
atopic eczema4MONDO:0004980EFO:0000274
ankylosing spondylitis4MONDO:0005306EFO:0003898
contact dermatitis4MONDO:0005480EFO:0005319
tenosynovitis4MONDO:0004855EFO:1001435
psoriasis4MONDO:0005083EFO:0000676
meningeal tuberculosis4MONDO:0006042EFO:1000039
frozen shoulder4MONDO:0006763EFO:1000941
dermatomyositis4MONDO:0016367EFO:0000398
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
autoimmune thrombocytopenic purpura4MONDO:0008558EFO:0007160
mycosis fungoides4MONDO:0009691EFO:1001051
subacute thyroiditis4MONDO:0006982EFO:1001194
lymphoma4MONDO:0005062EFO:0000574
optic neuritis4MONDO:0005885EFO:0007405
pulmonary tuberculosis4MONDO:0006052EFO:1000049
dermatitis herpetiformis4MONDO:0015614EFO:1000684
seborrheic dermatitis4MONDO:0006608EFO:1000764
posterior uveitis4MONDO:0006918EFO:1001119
leukemia4MONDO:0005059EFO:0000565
psoriatic arthritis4MONDO:0011849EFO:0003778
Stevens-Johnson syndrome4MONDO:0018229EFO:0004276
pemphigus vulgaris4MONDO:0008219EFO:0004719
arthritic joint disease4MONDO:0005578EFO:0005856
chronic beryllium disease4MONDO:0015274EFO:0007168
eosinophilic pneumonia4MONDO:0005749EFO:0007257
trichinellosis4MONDO:0019444EFO:0007520
thrombocytopenia4MONDO:0002049HP:0001873
nephrotic syndrome4MONDO:0005377EFO:0004255
atopic conjunctivitis4MONDO:0005642EFO:0007141
ophthalmic herpes zoster4MONDO:0005883EFO:0007403
erythema multiforme4MONDO:0006545EFO:1000694
iritis4MONDO:0006814EFO:1000997
sympathetic ophthalmia4MONDO:0019198EFO:1001205
aplastic anemia4MONDO:0015909HP:0001915
hypercalcemia disease4MONDO:0001566HP:0003072
juvenile dermatomyositis4MONDO:0008054EFO:0000557
neoplasm4MONDO:0005070EFO:0000616
myocarditis4MONDO:0004496EFO:0009609
synovitis4MONDO:0002400EFO:0008997
keratitis4MONDO:0003085EFO:0009449
exfoliative dermatitis4MONDO:0043233EFO:0009456
epicondylitis4MONDO:0001875EFO:1001896
iridocyclitis4MONDO:0004773HP:0001094
chorioretinitis4MONDO:0004674HP:0012424
choroiditis4MONDO:0001280MONDO:0001280
chronic primary adrenal insufficiency4MONDO:0015129MONDO:0015128
pemphigus4MONDO:0006594EFO:1000749
type III hypersensitivity disease4MONDO:0007004EFO:1001222
asthma4MONDO:0004979MONDO:0004979
osteoarthritis4MONDO:0005178MONDO:0005178
multiple sclerosis4MONDO:0005301MONDO:0005301
congenital adrenal hyperplasia4MONDO:0018479MONDO:0008728
sarcoidosis4MONDO:0019338MONDO:0019338
endocrine system disorder4MONDO:0005151EFO:0001379
brain neoplasm4MONDO:0021211EFO:0003833
adrenal gland disorder4MONDO:0005495EFO:0005539
peptic ulcer disease4MONDO:0004247HP:0004398
anemia4MONDO:0002280MONDO:0002280
bursitis4MONDO:0002471MONDO:0002471
spondylitis4MONDO:0003937MONDO:0003937
systemic lupus erythematosus4MONDO:0007915MONDO:0007915
nasal cavity polyp3MONDO:0006314EFO:1000391
pulmonary sarcoidosis3MONDO:0001708DOID:13406
sciatica3MONDO:0024333HP:0011868
granulomatosis with polyangiitis3MONDO:0012105EFO:0005297
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341
heart failure3MONDO:0005252EFO:0003144
plasma cell myeloma3MONDO:0009693EFO:0001378
prostate carcinoma3MONDO:0005159EFO:0001663
myasthenia gravis3MONDO:0009688EFO:0004991
sinusitis3MONDO:0005961EFO:0007486
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
prostate adenocarcinoma3MONDO:0005082EFO:0000673
urticaria3MONDO:0005492EFO:0005531
IgA glomerulonephritis3MONDO:0005342EFO:0004194
graft versus host disease3MONDO:0013730EFO:0004599
uveitis3MONDO:0020283EFO:1001231
perennial allergic rhinitis3MONDO:0024332EFO:1001417
mantle cell lymphoma3MONDO:0018876EFO:1001469
B-cell chronic lymphocytic leukemia3MONDO:0004948EFO:0000095
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
Hodgkins lymphoma3MONDO:0004952EFO:0000183
metastatic prostate carcinoma3MONDO:0004956EFO:0000196
T-cell acute lymphoblastic leukemia3MONDO:0004963EFO:0000209
peripheral T-cell lymphoma, not otherwise specified3MONDO:0004964EFO:0000211
acute myeloid leukemia3MONDO:0018874EFO:0000222
cardiomyopathy3MONDO:0004994EFO:0000318
congestive heart failure3MONDO:0005009EFO:0000373
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
neuroblastoma3MONDO:0005072EFO:0000621
sarcoma3MONDO:0005089EFO:0000691
idiopathic pulmonary fibrosis3MONDO:0800504EFO:0000768
kidney disorder3MONDO:0005240EFO:0003086
heart disorder3MONDO:0005267EFO:0003777
chronic kidney disease3MONDO:0005300EFO:0003884
membranous glomerulonephritis3MONDO:0005376EFO:0004254
lymphoid leukemia3MONDO:0005402EFO:0004289
anti-neutrophil antibody associated vasculitis3MONDO:0005435EFO:0004826
lupus nephritis3MONDO:0005556EFO:0005761
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
Langerhans cell histiocytosis3MONDO:0018310EFO:1000318
microscopic polyangiitis3MONDO:0019124EFO:1000784
temporal arteritis3MONDO:0008538EFO:1001209
hypereosinophilic syndrome3MONDO:0015691EFO:1001467
vasculitis3MONDO:0018882EFO:0006803
polymyalgia rheumatica3MONDO:0019735EFO:0008518
intermediate uveitis3MONDO:0006806EFO:1000986
central nervous system neoplasm3MONDO:0006130EFO:1000158
breast neoplasm3MONDO:0021100MONDO:0007254
thrombotic thrombocytopenic purpura3MONDO:0018896MONDO:0018896
follicular lymphoma3MONDO:0018906MONDO:0018906
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
B-cell acute lymphoblastic leukemia3MONDO:0004947EFO:0000094
Waldenstrom macroglobulinemia3MONDO:0100280MONDO:0000432
IgG4-related retroperitoneal fibrosis3MONDO:0018848MONDO:0018848
bullous pemphigoid3MONDO:0019082EFO:0007187
soft tissue sarcoma3MONDO:0018078EFO:1001968
mature T-cell and NK-cell non-Hodgkin lymphoma3MONDO:0000430MONDO:0000430
Alzheimer disease3MONDO:0004975MONDO:0004975
cystic fibrosis3MONDO:0009061MONDO:0009061
Duchenne muscular dystrophy3MONDO:0010679MONDO:0010679
tuberculosis3MONDO:0018076MONDO:0018076
pericarditis3MONDO:0005904EFO:0007427
plasma cell neoplasm3MONDO:0004959EFO:0000200
marginal zone lymphoma3MONDO:0017604EFO:1000630
prostate cancer3MONDO:0008315MONDO:0021259
myelodysplastic syndrome2MONDO:0018881EFO:0000198
hepatitis C virus infection2MONDO:0005231EFO:0003047
autoimmune disease2MONDO:0007179EFO:0005140
primary myelofibrosis2MONDO:0009692EFO:0002430
lung disorder2MONDO:0005275EFO:0003818
hemangioma2MONDO:0006500EFO:1000635
alcoholic hepatitis2MONDO:0001505EFO:1001345
hepatocellular carcinoma2MONDO:0007256EFO:0000182
angioimmunoblastic T-cell lymphoma2MONDO:0004977EFO:0000255
Burkitt lymphoma2MONDO:0007243EFO:0000309
essential thrombocythemia2MONDO:0005029EFO:0000479
melanoma2MONDO:0005105EFO:0000756
HIV infectious disease2MONDO:0005109EFO:0000764
acquired polycythemia vera2MONDO:0009891EFO:0002429
thymus neoplasm2MONDO:0005197EFO:0002626
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
relapsing-remitting multiple sclerosis2MONDO:0005314EFO:0003929
focal segmental glomerulosclerosis2MONDO:0100313EFO:0004236
hearing loss disorder2MONDO:0005365EFO:0004238
autoimmune hepatitis2MONDO:0016264EFO:0005676
cholesterol embolism2MONDO:0005568EFO:0005801
eosinophilic granulomatosis with polyangiitis2MONDO:0015943EFO:0007208
vestibular neuronitis2MONDO:0006008EFO:0007537
immunoglobulin A vasculitis2MONDO:0019167EFO:1000965
sensorineural hearing loss disorder2MONDO:0020678EFO:1001176
autoimmune hemolytic anemia2MONDO:0020108EFO:1001264
AIDS2MONDO:0012268EFO:0000765
Bell’s palsy2MONDO:0005665EFO:0007167
HIV-associated nephropathy2MONDO:0005798EFO:0007313
stiff-person syndrome2MONDO:0008491EFO:0007498
lichen planus, oral2MONDO:0043923EFO:0008517
pulmonary fibrosis2MONDO:0002771EFO:0009448
Takayasu arteritis2MONDO:0017991EFO:1001857
myeloproliferative neoplasm2MONDO:0020076EFO:0002428
neuromyelitis optica2MONDO:0019100EFO:0004256
viral pneumonia2MONDO:0006012EFO:0007541
Guillain-Barre syndrome, familial2MONDO:0007691EFO:0009538
blast phase chronic myelogenous leukemia, BCR-ABL1 positive2MONDO:0006115EFO:1000131
opsoclonus-myoclonus syndrome2MONDO:0015247EFO:1001383
interstitial nephritis2MONDO:0001085MONDO:0001085
kidney cancer2MONDO:0002367MONDO:0002367
lung neoplasm2MONDO:0021117MONDO:0008903
Castleman disease2MONDO:0015564MONDO:0015564
T-cell non-Hodgkin lymphoma2MONDO:0015760MONDO:0015760
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
adrenocortical insufficiency2MONDO:0000004EFO:0009491
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
allergic disease2MONDO:0005271MONDO:0005271
hemophilia A2MONDO:0010602MONDO:0010602
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
lymphoproliferative syndrome2MONDO:0016537MONDO:0016537
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
drug-induced liver injury2MONDO:0005359EFO:0004228
lymphoid neoplasm2MONDO:0005157EFO:0001642
CD4+/CD56+ hematodermic neoplasm2MONDO:0019467EFO:0010580
B-cell non-Hodgkin lymphoma2MONDO:0015759EFO:1001938
respiratory syncytial virus infectious disease1MONDO:0001577EFO:1001413
hematologic disorder1MONDO:0005570HP:0001871
glucose intolerance1MONDO:0001076HP:0001952
Gaucher disease1MONDO:0018150Orphanet:77260
Canavan disease1MONDO:0010079MONDO:0010079
frontotemporal dementia1MONDO:0017276MONDO:0017276
Fanconi anemia1MONDO:0019391MONDO:0019391
status asthmaticus1MONDO:0004766EFO:0008590
primary effusion lymphoma1MONDO:0018842EFO:1000491
Diamond-Blackfan anemia1MONDO:0015253MONDO:0015253
type 2 diabetes mellitus0MONDO:0005148MONDO:0005148

23 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1,357.

Phase distribution

PhaseTrials
PHASE2516
PHASE3313
PHASE4135
PHASE1127
PHASE1/PHASE2111
Not specified90
PHASE2/PHASE351
EARLY_PHASE114

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03016741PHASE4ACTIVE_NOT_RECRUITINGCognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
NCT03153527PHASE4RECRUITINGTaper Or Abrupt Steroid Stop: TOASSTtrial
NCT03760835PHASE4RECRUITINGCongenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment
NCT03829371PHASE4ACTIVE_NOT_RECRUITINGSTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT04314193PHASE4ACTIVE_NOT_RECRUITINGEffectiveness of Methotrexate Versus Prednisone as First-line Therapy for Pulmonary Sarcoidosis
NCT04376216PHASE4RECRUITINGPrednisolone Treatment in Acute Interstitial Nephritis
NCT04568837PHASE4NOT_YET_RECRUITINGSteroids After Spine Fusion Surgery
NCT04654988PHASE4RECRUITINGStudy to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.
NCT04788823PHASE4ACTIVE_NOT_RECRUITINGThe Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal
NCT04875702PHASE4RECRUITINGTreat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
NCT05428826PHASE4RECRUITINGEarly Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis
NCT05457257PHASE4ACTIVE_NOT_RECRUITINGClinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
NCT05522465PHASE4RECRUITINGShort-course High-dose Prednisone and Dexamethasone in Children With ITP
NCT05578456PHASE4NOT_YET_RECRUITINGEffect of Prednisone and Aspirin on IVF-ET Outcome Among Patients With Thyroid Autoimmunity
NCT05772871PHASE4RECRUITINGThe Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children
NCT05867329PHASE4RECRUITINGFeasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis
NCT06040255PHASE4ENROLLING_BY_INVITATIONFocal Cerebral Arteriopathy Steroid Trial
NCT06090890PHASE4RECRUITINGAnti-inflammatory Therapy for Recurrent In-stent Restenosis
NCT06364319PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
NCT06498089PHASE4RECRUITINGA Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu’s Arteritis
NCT06603662PHASE4RECRUITINGSystemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department
NCT06635863PHASE4ENROLLING_BY_INVITATIONComparing Immune System Suppression to Medication for Unexplained Heart Function and Irregular Heartbeat
NCT06833814PHASE4NOT_YET_RECRUITINGDOSE Trial: Optimal Dose of Oral Corticosteroids to Treat Asthma Exacerbations
NCT07221838PHASE4RECRUITINGA Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
NCT07426484PHASE4NOT_YET_RECRUITINGCosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
NCT07451665PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu’s Arteritis
NCT00133172PHASE4TERMINATEDEffect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection
NCT00149994PHASE4COMPLETEDCyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
NCT00195429PHASE4COMPLETEDA Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients
NCT00203047PHASE4TERMINATEDAssessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
NCT00204737PHASE4COMPLETEDShort Course Glucocorticoid Treatment for PTSD
NCT00275535PHASE4COMPLETEDThe Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
NCT00307671PHASE4COMPLETEDTreatment of Necrotizing Vasculitides for Patients Older Than 65 Years
NCT00371826PHASE4COMPLETEDSOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus
NCT00374231PHASE4COMPLETEDSingle Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients
NCT00393367PHASE4COMPLETEDBudesonide Inhalation Suspension for Acute Asthma in Children
NCT00419926PHASE4COMPLETEDEvaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients
NCT00472030PHASE4COMPLETEDEfficacy and Safety of Omalizumab in Bullous Pemphigoid
NCT00494897PHASE4COMPLETEDPETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
NCT00526175PHASE4COMPLETEDLAL-BR/2001: Study Treatment to Low Risk ALL

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 13 clinical and 66 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

173 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR3C1
PODOFILOXChEMBL + PubChemPhase 4 (approved)NR3C1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)NR3C1
ACENOCOUMAROLChEMBLPhase 4 (approved)NR3C1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
AMCINONIDEChEMBLPhase 4 (approved)NR3C1
AMIODARONEChEMBLPhase 4 (approved)NR3C1
APREPITANTChEMBLPhase 4 (approved)NR3C1
AURANOFINChEMBLPhase 4 (approved)NR3C1
BAZEDOXIFENEChEMBLPhase 4 (approved)NR3C1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BENZBROMARONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE PHOSPHORIC ACIDChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE VALERATEChEMBLPhase 4 (approved)NR3C1
BUDESONIDEChEMBLPhase 4 (approved)NR3C1
BUTOCONAZOLEChEMBLPhase 4 (approved)NR3C1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR3C1
CANRENONEChEMBLPhase 4 (approved)NR3C1
CHLORMADINONEChEMBLPhase 4 (approved)NR3C1
CICLESONIDEChEMBLPhase 4 (approved)NR3C1
CLOBETASOL PROPIONATEChEMBLPhase 4 (approved)NR3C1
CLOFAZIMINEChEMBLPhase 4 (approved)NR3C1
CLOTRIMAZOLEChEMBLPhase 4 (approved)NR3C1
CORTISONEChEMBLPhase 4 (approved)NR3C1
DANAZOLChEMBLPhase 4 (approved)NR3C1
DAUNORUBICINChEMBLPhase 4 (approved)NR3C1
DEFLAZACORTChEMBLPhase 4 (approved)NR3C1
DESOGESTRELChEMBLPhase 4 (approved)NR3C1
DESONIDEChEMBLPhase 4 (approved)NR3C1
DESOXIMETASONEChEMBLPhase 4 (approved)NR3C1
DESOXYCORTICOSTERONE PIVALATEChEMBLPhase 4 (approved)NR3C1
DEXAMETHASONEChEMBLPhase 4 (approved)NR3C1
DEXTROTHYROXINEChEMBLPhase 4 (approved)NR3C1
DIENESTROLChEMBLPhase 4 (approved)NR3C1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)NR3C1
DIFLORASONE DIACETATEChEMBLPhase 4 (approved)NR3C1
DOXORUBICINChEMBLPhase 4 (approved)NR3C1
DROSPIRENONEChEMBLPhase 4 (approved)NR3C1
ECONAZOLEChEMBLPhase 4 (approved)NR3C1
EFAVIRENZChEMBLPhase 4 (approved)NR3C1
ENZALUTAMIDEChEMBLPhase 4 (approved)NR3C1
EPLERENONEChEMBLPhase 4 (approved)NR3C1
ESTRADIOLChEMBLPhase 4 (approved)NR3C1
ESTRIOLChEMBLPhase 4 (approved)NR3C1
ETHINYL ESTRADIOLChEMBLPhase 4 (approved)NR3C1
EXEMESTANEChEMBLPhase 4 (approved)NR3C1
FELODIPINEChEMBLPhase 4 (approved)NR3C1
FLUDROCORTISONEChEMBLPhase 4 (approved)NR3C1
FLUNISOLIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINOLONE ACETONIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINONIDEChEMBLPhase 4 (approved)NR3C1
FLUOROMETHOLONEChEMBLPhase 4 (approved)NR3C1
FLUOXYMESTERONEChEMBLPhase 4 (approved)NR3C1
FLURANDRENOLIDEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR3C1
GLUCAGONChEMBLPhase 4 (approved)NR3C1
HALCINONIDEChEMBLPhase 4 (approved)NR3C1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot